Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Will Merck and Pfizer Impress Investors This Earnings Season?

Earnings season has made its way through many of big pharma's biggest names, but two of the industry's household players -- Merck (NYSE: MRK  ) and Pfizer (NYSE: PFE  )  -- are set to report their third-quarter performances next week. While both companies are fighting against the patent cliff, each has its own challenges and hopes ahead. 

Merck's struggling with a retooling after announcing it will cut back its extensive research and development division, a costly endeavor that some investors have called to be pared in the recent past. Merck's own pipeline has struggled to impress lately, and while Wall Street isn't expecting much this earnings season, this company needs to show it's on the right path to success. Pfizer, meanwhile, boasts of a strong pipeline headed forward, but can its potential blockbuster drugs, such as blood thinner Eliquis and inflammatory treatment Xeljanz, impress investors after a rocky 2013 so far?

Find out in the video below, where Fool contributor Dan Carroll tells you what to look for when Merck and Pfizer announce their earnings next week and what the roads ahead for each of these companies could hold.

Which dividend stock is right for your portfolio?
Merck and Pfizer are two of the Dow's top dividend stocks, but they aren't the only blue chips that will light up income investors' eyes. If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2700153, ~/Articles/ArticleHandler.aspx, 9/28/2016 1:42:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,223.21 -5.09 -0.03%
S&P 500 2,158.56 -1.37 -0.06%
NASD 5,297.94 -7.77 -0.15%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 1:27 PM
MRK $62.90 Up +0.33 +0.53%
Merck and Co. CAPS Rating: ****
PFE $33.72 Down -0.12 -0.34%
Pfizer CAPS Rating: ****
BMY $55.03 Down -0.72 -1.28%
Bristol-Myers Squi… CAPS Rating: ****
GSK $43.54 Up +0.22 +0.51%
GlaxoSmithKline CAPS Rating: ***